Amgen, Inc. has recalled MVASI (bevacizumab-awwb) Injection, 100 mg/4 ml, after discovering a defect where the vial container crimp may be loose. This recall affects approximately 15,823 units that were distributed nationwide to hospitals, clinics, and pharmacies. The loose seal could result in a loss of container integrity, potentially leading to leakage or medication contamination. No injuries or incidents have been reported to date.
A loose crimp defect can compromise the sterile seal of the vial, potentially allowing microorganisms to contaminate the medication. If contaminated medication is administered intravenously, it could cause serious infections or other adverse health consequences for the patient.
Recall #: D-0855-2022; Total Quantity: 15,823 units
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.